This condition is a chronic lung disease characterized by progressivescarring of the lungs, which often has a peripheral distribution.Modulation of bromodomain-containing protein 4 (BRD4), either throughsiRNA-mediated silencing or pan-BET inhibitors, has been shown tohalt fibrotic processes in lung-derived cells, including fibroblastsand epithelial cells, as well as in multiple animal models of lungremodeling. Nevertheless, clinical trialswith oral BET inhibitors have raised safety concerns, underscoringthe need for safer and more selective BET-targeting strategies. The gene discussed is DNER; the disease is chronic lung disease.